We are delighted to have contributed to the positive outcomes from the Freya Bioscience’s first Phase 1 clinical study of its lead asset FB101, which is an investigational immunotherapeutic targeting vaginal microbial dysbiosis.
Together also with Atlantia Clinical Trials, we evaluated the longitudinal change in the vaginal microbiome after vaginal administration of FB101 in women with asymptomatic vaginal tract dysbiosis, and found that FB101 let to a rapid and sustained switch from a dysbiotic to a Lactobacillus-dominated microbiome. Half of the women showed that engraftment of the Lactobacilli species was established, as determined by strain-level engraftment analysis. Freya intends to expand studies of FB101 for improving fertility outcomes and enhancing the success rates of IVF.
Read more in the Microbiome Times.